US EditionOzempic for fatty liver disease: What to know about the new findings
- On April 30, 2025, researchers announced that a 72-week clinical trial found semaglutide effective in improving liver condition among patients suffering from metabolic dysfunction-associated steatohepatitis .
- The trial arose from limited treatment options for MASH, a progressive liver disease linked to obesity and type 2 diabetes that often causes no symptoms until advanced stages.
- The phase 3 ESSENCE trial enrolled 800 participants globally to evaluate semaglutide versus placebo in adults diagnosed with metabolic dysfunction-associated steatohepatitis exhibiting stage 2 or 3 liver fibrosis, focusing on changes in liver scarring, fat accumulation, and inflammation.
- By week 72, 62.9% of patients receiving semaglutide showed steatohepatitis resolution without any progression of liver fibrosis, compared to 34.3% of those given placebo, resulting in an estimated difference of 28.7% .
- Novo Nordisk plans to seek regulatory approval in the US and EU, and experts expect semaglutide could reduce cirrhosis risk and represent a significant advancement for patients with this serious liver condition.
64 Articles
64 Articles
Ozempic Shows Promise in Treating a Severe Form of Liver Disease, Study Finds
Fact checked by Nick BlackmerMilko / Getty ImagesIn a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH.Patients also saw improvements in weight, blood sugar, and insulin resistance.Experts say semaglutide may be a much-needed treatment option for a liver disease with few current therapies.Ozempic is effective in treating a severe form of liver disease that affects nearly 2 million Americans, according to a…
Fat jabs can treat liver disease affecting one in five people, finds trial
FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of patients with non-alcoholic fatty liver disease. GettyFat jabs can cut inflammation in two thirds of patients with non-alcoholic fatty liver disease[/caption] Nonalcoholic Fatty Liver Disease (NAFLD) a buildup of fat in the liver The medicine is used in weight-loss injection Wegovy and diabetes treatment Ozempic. Fatty li…
Chatham Star Tribune
ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM
Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo.…
Coverage Details
Bias Distribution
- 47% of the sources lean Left
To view factuality data please Upgrade to Premium
